###begin article-title 0
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 175 180 <span type="species:ncbi:9606">human</span>
Tamoxifen is effective for endocrine treatment of oestrogen receptor-positive breast cancers but ultimately fails due to the development of resistance. A functional screen in human breast cancer cells identified two BCAR genes causing oestrogen-independent proliferation. The BCAR1 and BCAR3 genes both encode components of intracellular signal transduction, but their direct effect on breast cancer cell proliferation is not known. The aim of this study was to investigate the growth control mediated by these BCAR genes by gene expression profiling.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
We have measured the expression changes induced by overexpression of the BCAR1 or BCAR3 gene in ZR-75-1 cells and have made direct comparisons with the expression changes after cell stimulation with oestrogen or epidermal growth factor (EGF). A comparison with published gene expression data of cell models and breast tumours is made.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
Relatively few changes in gene expression were detected in the BCAR-transfected cells, in comparison with the extensive and distinct differences in gene expression induced by oestrogen or EGF. Both BCAR1 and BCAR3 regulate discrete sets of genes in these ZR-75-1-derived cells, indicating that the proliferation signalling proceeds along distinct pathways. Oestrogen-regulated genes in our cell model showed general concordance with reported data of cell models and gene expression association with oestrogen receptor status of breast tumours.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
The direct comparison of the expression profiles of BCAR transfectants and oestrogen or EGF-stimulated cells strongly suggests that anti-oestrogen-resistant cell proliferation is not caused by alternative activation of the oestrogen receptor or by the epidermal growth factor receptor signalling pathway.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 430 438 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#945; </italic>
###xml 442 448 438 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#946;</italic>
###xml 642 643 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 644 645 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 750 751 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 752 753 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 895 896 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 897 898 879 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
The development and progression of breast cancer is dependent on steroid sex hormones and polypeptide growth factors. Oestrogen action has been implicated in the development of breast cancers and frequently contributes to tumour growth. The action of oestrogen is relayed through its specific nuclear oestrogen receptor (ER), which belongs to the family of ligand-inducible transcription factors [1,2]. Two distinct genes for ER (ERalpha and ERbeta) have been identified. The role of ERalpha in breast cancer has been studied extensively and this receptor has been the subject of targeted therapies. Less information is available for ERbeta [3,4], which exhibits differential tissue distribution and alternative responses to selective ER modulators [5,6]. Epidermal growth factor receptor (EGFR) expression is mainly present in ERalpha-negative breast tumours and is a marker of poor prognosis [7,8].
###end p 11
###begin p 12
###xml 393 394 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 395 397 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The frequent occurrence of ERalpha in breast tumours (about 75%) has been used as a guide for treatment. Endocrine treatment regimens, which either reduce the endogenous oestrogen levels (for example aromatase inhibitors) or interfere with ERalpha activation (anti-oestrogen such as tamoxifen), have been shown to block tumour growth and in some cases cause tumour reduction or disappearance [9,10]. However, the resistance of ERalpha-positive breast tumours is a severe limitation of endocrine treatment. About half of the ERalpha-positive breast tumours completely fail to respond (intrinsic resistance), whereas all responsive breast cancers ultimately progress and become resistant to the treatment (acquired resistance).
###end p 12
###begin p 13
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 207 209 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 210 212 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 394 395 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 396 398 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 527 529 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 603 607 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR</italic>
###xml 716 718 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 725 731 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
###xml 914 916 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 923 929 919 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 1049 1056 1045 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p130Cas</italic>
###xml 1064 1066 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1163 1165 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1166 1168 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1378 1380 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1381 1383 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 996 1001 <span type="species:ncbi:9606">human</span>
###xml 1019 1022 <span type="species:ncbi:10116">rat</span>
###xml 1192 1197 <span type="species:ncbi:9606">human</span>
Despite much effort, the basis for the resistance of breast cancer to endocrine treatments is still poorly understood [11]. In general, tamoxifen resistance is not accompanied by loss of ERalpha expression [12,13]. Previous work has shown that the treatment outcome might be the result of a delicate balance between positive and negative regulators acting in concert with the hormone receptor [2,14]. In addition, alternative growth regulatory pathways might be available to tumour cells, permitting escape from the treatment [15]. We have searched for specific Breast Cancer Anti-oestrogen Resistance (BCAR) genes involved in the progression of oestrogen-dependent breast cancer cells to anti-oestrogen resistance [16]. The BCAR3 gene was shown to control anti-oestrogen-resistant cell growth in two different oestrogen-dependent cell lines and its product exhibits features of a cytoplasmic signalling molecule [17]. The BCAR1 gene causes anti-oestrogen resistance in our cell model and is the human homologue of the rat Crk-associated substrate (p130Cas) gene [18]. This docking protein has been implicated in many types of intracellular signalling processes [19,20]. Moreover, studies of human breast cancer specimens have shown that high BCAR1 expression is associated with poor prognosis and also predicts a poor response of recurrent disease to treatment with tamoxifen [21-24].
###end p 13
###begin p 14
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 161 168 <span type="species:ncbi:9606">patient</span>
Recent developments in global gene expression profiling have elegantly shown their applicability in tumour classification and in predicting the prognosis of the patient [25-30]. Furthermore, studies in model systems have highlighted the use of gene expression profiling for unravelling delicate cellular processes.
###end p 14
###begin p 15
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
The aim of our study was to use gene expression profiling to investigate the anti-oestrogen-resistant growth regulatory process induced by overexpression of the BCAR genes and to establish whether oestrogen or epidermal growth factor (EGF) signalling are involved.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Breast cancer cell lines cultures and RNA preparation
###end title 17
###begin p 18
###xml 201 203 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 259 261 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 337 339 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 385 387 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 558 560 555 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1364 1366 1360 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 119 125 <span type="species:ncbi:9913">bovine</span>
###xml 126 130 <span type="species:ncbi:9913">calf</span>
The oestrogen-dependent human breast cancer cell line ZR-75-1 was maintained in RPMI 1640 medium supplemented with 10% bovine calf serum and 1 nM 17 beta-oestradiol (R/BCS/E2) as described previously [16]. The derived EGFR-transfectant cell line ZR/HERc(1A) [31], hereafter referred to as ZR/EGFR, a BCAR1-transfectant cell line (4A12) [18] and a BCAR3-transfectant cell line (B3-10) [17] were also maintained in R/BCS/E2 medium. For short-term induction experiments, cells were cultured for 4 days in regular medium lacking added oestrogen (R/BCS) in 162 cm2 flasks, given fresh R/BCS medium 24 hours before manipulation, and cultured for 6 hours in the presence of 100 nM oestradiol or 1 muM ICI 164,384 (or ethanol vehicle alone) in R/BCS medium. Hormones and anti-hormones were provided by N.V. Organon (Oss, The Netherlands). For long-term induction experiments, cells were grown for 7 days in R/BCS/E2 medium or R/BCS medium containing 10 ng/ml EGF (Roche Diagnostics Nederland B.V., Almere, The Netherlands). Medium was replaced after 3 days and at 24 hours before harvest. After completion of the culture, the medium was removed and cells were lysed directly with 16-20 ml of RNAzol B solution (Campro Scientific, Veenendaal, the Netherlands). RNA was prepared as described by the manufacturer, quantified and checked for integrity on agarose gels. Poly(A)+ mRNA was prepared from pooled total RNA samples of two independent cultures by two cycles of binding to oligo(dT) with the use of OligoTex (Qiagen/Westburg B.V., Leusden, The Netherlands), and checked for integrity and contamination with ribosomal RNA by capillary electrophoresis (Lab-on-a-Chip, Agilent Technologies 2100 bioanalyzer, Amstelveen, The Netherlands).
###end p 18
###begin title 19
Expression analysis
###end title 19
###begin p 20
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 704 706 704 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 783 785 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 984 986 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
Production of Cy5-labelled and Cy3-labelled cDNA from the purified mRNA, hybridisation of the UniGEMV cDNA microarrays and quantification of the signals were performed by Incyte Genomics (Mountain View, CA, USA) as described previously [32]. Two batches of UniGEMV2 microarrays were used for these experiments. All hybridisations (Table 1) were performed in duplicate with a fluor reversal to minimise possible bias caused by the molecular structure of the Cy3 and Cy5 dyes. Data analysis was performed with the Rosetta Resolver software package (v 3.2) with an Incyte/UniGEM microarray error model (Rosetta Inpharmatics Inc., Kirkland, WA, USA). Genes exhibiting at least once a significant difference (P </= 0.01) in expression in these experiments were used for further analysis (n = 2373). In addition to the actual measured gene expression ratios we calculated the expression ratios between different experimental conditions from two measurements that contained a common sample [33]. Because the calculated gene expression ratios were in good agreement with available actual measurements, we used these calculations as 'virtual experiments'.
###end p 20
###begin p 21
For hierarchical clustering of the measured and calculated expression ratios, we used Resolver software (average linkage agglomerative clustering using Euclidean distance and weighted by error) and Spotfire Decision Site 7.1 analysis package (Spotfire Inc., Somerville, MA, USA) using the Unweighted Paired-Group Method with Arithmetic mean (UPGMA) and Pearson's correlation as a similarity measure. Information on the function of genes has been retrieved from various public databases (for example PubMed, OMIN, GENECARD, KEGG and GO) and from the LifeSeq Gold database (Incyte Genomics). Expression data publicly available from prostate cancer, breast cancer and cell lines were linked to our data by means of the Unigene cluster number.
###end p 21
###begin p 22
###xml 493 495 489 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The strength of the relations between oestrogen and EGF-induced gene expression (log [ratio]) data was tested by Spearman rank correlation. The relations between categorised expression data (differential expression [DE] >/= 1.60; 1.60 > DE > - 1.60; DE </= - 1.60) and gene association with tumour ER status (positive or negative) were tested by Spearman rank correlation. All computations were done with the STATA statistical package, release 8.0 (STATA Corp., College Station, TX, USA). All P values are two-sided.
###end p 22
###begin title 23
Quantitative RT-PCR
###end title 23
###begin p 24
###xml 126 128 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 155 161 153 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12&#8211;18 </sub>
###xml 1455 1456 1392 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 2284 2290 2150 2156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
For quantitative reverse transcriptase-mediated polymerase chain reaction (RT-PCR), 2.5 mug of total RNA (or 100 ng of poly(A)+ mRNA), 0.8 mug of oligo(dT)12-18 (Invitrogen Corporation) and 0.5 mug of random hexamer (Pharmacia) in 20 mul of RNase-free water were heated for 5 min at 65degreesC and cooled on ice. The final reaction of 40 mul contained 0.4 mM dNTPs (Pharmacia), 60 units of RNAseOUT and 300 units of SuperscriptII Reverse Transcriptase (Invitrogen). Incubations were for 2 min at 0degreesC, 10 min at 25degreesC, 50 min at 42degreesC and 10 min at 55degreesC; the reaction was stopped by heating for 15 min at 75degreesC. RNA was destroyed by treatment with 2 units of RNAseH (Promega) for 30 min at 37degreesC. cDNA products were diluted to 100 mul with 10 mM Tris/HCl pH 7.5; these stocks were stored at -80degreesC. Forty cycles of amplification of 5 mul of cDNA stocks in distilled water (Invitrogen) diluted 1:19 were performed with an SYBR green PCR mix (Applied Biosystems or Stratagene) and 0.33 muM forward and reverse primers in a volume of 25 mul on a ABI Prism 7700 (Applied Biosystems) in accordance with the recommended protocol. Primer annealing was performed at 60 or 62degreesC. A dilution series (1:4 to about 1:10,000) of a reference cDNA pool (mixture of cDNA preparations of RNA derived from six different cell lines) was used for normalising gene expression. The intron-spanning gene primers used are listed in Table 2. The cycling conditions were as follows: denaturation for 10 min at 95degreesC; 40 cycles (15 s at 95degreesC, 30 s at 60degreesC (CTSD, TFF1 and MYC) or 62degreesC, 10 s ramping to 72degreesC, 20 s at 72degreesC, 10 s ramping to 79degreesC, 20 s at 79degreesC). Data were collected at 72 and 79degreesC and were analysed at 79degreesC. At the end of the amplification, the melting curve of the products was determined. PCR products showed discrete melting curves and specific bands of correct lengths on agarose gels after 40 cycles of amplification. We also used Assays-on-Demandtrade mark (Applied Biosystems) for various genes, in accordance with the manufacturer's protocol. cDNA (5 mul, diluted 1:19 or 1:39) was measured in 25 mul reactions with the TaqMan Universal PCR master Mix. All cDNA samples were normalised for HPRT1 levels (four independent measurements) and are presented relative to the gene level in ZR-75-1 cells maintained in R/BCS medium.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Overall gene expression
###end title 26
###begin p 27
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 583 585 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 933 950 931 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 1284 1301 1282 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 133 138 <span type="species:ncbi:9606">human</span>
To evaluate the effects of oestrogen, of EGF and of previously identified BCAR genes involved in oestrogen-independent growth of the human breast cancer cell line ZR-75-1, we determined the global gene expression in these cells by using UniGEMV2 cDNA microarrays. We performed direct comparisons of mRNA samples without the use of a general reference RNA sample (Table 1). Of the approximately 9000 sequences (about 88% represent known genes according to UNIGENE build no. 160) present on the microarray, the expression of 2373 genes (i.e. 26% of total sequences) was significantly (P </= 0.01) affected by either the oestrogen treatment or the EGF treatment or the BCAR transfections. Hierarchical clustering distributes the expression profiles according to the experimental culture conditions; that is, profiles of long-term oestrogen-treated cells were separated from short-term oestrogen-treated cells or BCAR-transfected cells (Additional file 1). The majority of the large changes in gene expression were observed in the oestrogen-stimulated or EGF-stimulated cultures. Hybridisation profiles of short-term oestrogen stimulation of ZR-75-1 cells and BCAR3-transfected cells are very similar and distinct from hybridisation profiles of long-term oestrogen-stimulated cell lines (Additional file 1). The EGF-stimulated ZR/EGFR cells as well as the BCAR1- and BCAR3-transfected cells exhibit clearly different profiles in comparison with the oestrogen-stimulated cultures. The comparison of BCAR-transfected cell lines with each other or with non-stimulated parental cells revealed modest changes in gene expression, indicating that gene expression differences in these BCAR cell lines are generally subtle. Below we discuss the expression profiles (average gene expression log(ratios) of the independent experiments) of a selection of 1006 genes exhibiting a |DE| >/= 1.60 in at least one of the actual or virtual experiments.
###end p 27
###begin title 28
###xml 59 64 <span type="species:ncbi:9606">human</span>
Effects of oestrogen and EGF on gene expression of ZR-75-1 human breast cancer cells
###end title 28
###begin p 29
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 527 528 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 533 550 529 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 821 826 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1 </italic>
###xml 833 838 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSTD </italic>
###xml 853 859 847 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 875 879 869 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR </italic>
###xml 1044 1045 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1067 1068 1061 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1068 1069 1062 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1069 1070 1063 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 1636 1637 1630 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1700 1704 1694 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMD1</italic>
###xml 1706 1710 1700 1704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2</italic>
###xml 1712 1717 1706 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 1719 1723 1713 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GJA1</italic>
###xml 1725 1730 1719 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEIS3</italic>
###xml 1732 1738 1726 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP140</italic>
###xml 1740 1746 1734 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1750 1754 1744 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STC1</italic>
###xml 1791 1796 1785 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIF1A</italic>
###xml 1798 1803 1792 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6ST</italic>
###xml 1805 1808 1799 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYB</italic>
###xml 1810 1814 1804 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PC4 </italic>
###xml 1818 1824 1812 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 1895 1912 1889 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">Additional file 3</xref>
###xml 2083 2084 2077 2078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2084 2086 2078 2080 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 2094 2096 2088 2090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
ZR-75-1 breast cancer cells are completely dependent on oestrogen for growth. In standard medium without added oestrogen, growth is strongly reduced. Addition of anti-oestrogen completely abolishes the growth of these cells [16]. Oestrogen-induced cell proliferation is mediated by the transcription activation function of the ERalpha. To identify the early effects (that is, the transcription targets) of oestrogen stimulation, the expression profile was analysed after a 6-hour high-dose pulse of 100 nM oestrogen. From Fig. 1 and Additional file 1 it is clear that limited changes in gene expression (115 genes with |DE| >/= 1.60) have occurred during this short treatment compared with mock-stimulated cultures. Over 75% of these genes seemed to be induced. Among these genes are well-known oestrogen targets such as TFF1 (PS2), CSTD (cathepsin D), CCND1 (cyclin D1) and PGR (progesterone receptor). These and several novel genes were rapidly induced by oestrogen both in the parental ZR-75-1 cells and in the BCAR3-transfected cells (Fig. 1 and Additional files 123). An extended picture emerges after continuous exposure to the regular dose of 1 nM oestrogen. About 400 genes exhibit consistent changes (at least 1.6-fold) in expression, of which about 60% of the sequences exhibit a significant decrease of gene expression (up to sevenfold) and 40% are increased (up to more than 10-fold). The genes specifically modulated by oestrogen comprise members of all functional compartments and processes in the cell. One-quarter of the early-induced genes remain expressed (DE > 1.60) during continuous exposure to oestrogen (see Fig. 1), whereas the expression of others is turned off (for example AMD1, BCL2, CCND1, GJA1, MEIS3, RIP140, RUNX1 and STC1) or even downregulated (for example HIF1A, IL6ST, MYB, PC4 and UGT2B7). Definitions of these and other and other gene names can be found in Additional file 3. Statistical analysis of all 1006 genes shows a clear positive correlation between early-induced gene expression and genes expressed after 7 days of oestrogen treatment (rs = 0.36, P < 0.0001).
###end p 29
###begin p 30
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 558 575 558 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 922 923 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 923 925 923 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 933 935 933 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1016 1017 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1017 1019 1017 1019 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1041 1046 1041 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1452 1453 1452 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
We have previously shown that the addition of EGF to the culture medium does not support growth of ZR-75-1 cells because of the absence of EGF receptors [31,34]. The introduction of EGFR into ZR-75-1 cells (ZR/EGFR) permits a response to EGF and can support proliferation independently of oestrogen [31]. Gene expression of ZR/EGFR cells stimulated with EGF for 7 days was directly compared with that of ZR-75-1 cells stimulated with oestrogen continuously. It is clear from this direct comparison that 247 genes are specifically altered more than 1.6-fold (Additional file 1). From the virtual experiment, which compares the EGF stimulation of ZR/EGFR cells with unstimulated ZR-75-1 cells, we can conclude that EGF modulates a large cohort of genes (707) at least 1.6-fold (Fig. 1). Statistical analysis of all 1006 genes shows a strong positive correlation for gene expression regulated by EGF and long-term oestrogen (rs = 0.67, P < 0.0001), but no significant association with genes induced early by oestrogen (rs = 0.16). As expected, EGFR is one of the most prominently changed genes in our analysis as a consequence of the transgene expression. In addition, the expression of genes implicated in signalling processes, cell adhesion and structure, protein modification, transport and metabolic processes is specifically regulated by treatment with EGF or shows a pronounced alteration in comparison with that in oestrogen-treated cultures (Fig. 1).
###end p 30
###begin title 31
Effects of overexpression of BCAR1 or BCAR3 in ZR-75-1 cells
###end title 31
###begin p 32
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 561 562 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 705 722 705 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
###xml 894 900 894 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
We have previously shown that stable overexpression of BCAR1 or BCAR3 induces cell proliferation independently of oestrogen and anti-oestrogen [17,18]. In an attempt to pinpoint the effects of these cytoplasmic signalling molecules on global gene expression in cultures without added oestrogen, we compared BCAR3 and BCAR1, and BCAR3 and ZR-75-1, directly on microarrays, and calculated the gene expression relation between BCAR1 and ZR-75-1 as a virtual experiment. A total of 79 genes exhibited consistent differences in expression of at least 1.6-fold (Fig. 1). Few genes are modulated solely by the overexpression of a BCAR gene; most are also a target for hormonal and/or EGF stimulation (Fig. 1 and Additional file 1). As expected, the largest observed difference (up to 15-fold) in these comparisons was derived from the BCAR3 transgene expression. No cDNA sequence corresponding to the BCAR1 gene was present on this microarray.
###end p 32
###begin p 33
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSTA</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DLG7</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FMOD</italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOLR1</italic>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXJ1</italic>
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPC242</italic>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5</italic>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS1</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIV1</italic>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NEDD4L</italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NELL2</italic>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH7 </italic>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBE2C</italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGK1</italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHA</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TPI1</italic>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALDOC</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO3 </italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PFKP</italic>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 589 606 589 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 679 683 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 685 688 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASS</italic>
###xml 690 695 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRIP1</italic>
###xml 697 701 697 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELL2</italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXM1</italic>
###xml 710 715 710 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPG2</italic>
###xml 717 720 717 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID1</italic>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R1</italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6ST</italic>
###xml 736 742 736 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS8</italic>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDZK1</italic>
###xml 751 754 751 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TK1</italic>
###xml 756 762 756 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPP3CA</italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TOMM20</italic>
###xml 772 778 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VIPR1 </italic>
###xml 830 831 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 974 979 974 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF3 </italic>
###xml 983 987 983 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGP </italic>
###xml 993 994 993 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1023 1025 1023 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BF</italic>
###xml 1027 1031 1027 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2</italic>
###xml 1033 1038 1033 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BIRC5</italic>
###xml 1040 1046 1040 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN1A</italic>
###xml 1048 1053 1048 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INADL</italic>
###xml 1055 1063 1055 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIAA0101</italic>
###xml 1065 1073 1065 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPKAPK2</italic>
###xml 1075 1078 1075 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYB</italic>
###xml 1080 1086 1080 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2RY10</italic>
###xml 1088 1091 1088 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PC4</italic>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRCP</italic>
###xml 1099 1103 1099 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCLN</italic>
###xml 1105 1114 1105 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAB6KIFL </italic>
###xml 1117 1123 1117 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIF20A</italic>
###xml 1126 1134 1126 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINA5</italic>
###xml 1136 1143 1136 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC7A2 </italic>
###xml 1147 1154 1147 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B11</italic>
Changes in gene expression specifically caused by BCAR3 overexpression in ZR-75-1 cells were seen for CSTA, DLG7, FMOD, FOLR1, FOXJ1, HSPC242, IGFBP5, LGALS1, LIV1, NEDD4L, NELL2, PCDH7 and UBE2C. In addition, a clear induction of several genes involved in glucose metabolism (PGK1, LDHA, TPI1, and moderate induction levels of ALDOC, ENO1, ENO3 and PFKP; Fig. 1) was observed. This coherent change in gene expression is unlikely to represent a culture artefact because no expression change was observed in these genes in BCAR3-transfected cells after 6 hours of induction with oestrogen (Additional file 1). Specifically altered genes in BCAR1-transfected ZR-75-1 cells include APOD, ASS, CRIP1, ELL2, FOXM1, HSPG2, ID1, IL1R1, IL6ST, LGALS8, PDZK1, TK1, PPP3CA, TOMM20, VIPR1 and various genes encoding ribosomal proteins (Fig. 1). A moderately opposing direction of gene expression change in these two transfectant cell lines compared with ZR-75-1 cells was indicated by TFF3 and MGP (Fig. 1). A set of genes (including BF, BCL2, BIRC5, CDKN1A, INADL, KIAA0101, MAPKAPK2, MYB, P2RY10, PC4, PRCP, OCLN, RAB6KIFL (= KIF20A), SERPINA5, SLC7A2 and UGT2B11) exhibited differential expression in both BCAR-transfected cell lines when compared with the parental cell line ZR-75-1.
###end p 33
###begin title 34
Verification of expression differences by quantitative PCR
###end title 34
###begin p 35
###xml 440 446 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT1 </italic>
###xml 722 726 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HMBS</italic>
###xml 775 779 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 893 894 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 982 986 982 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1043 1044 1043 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1073 1077 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1</italic>
###xml 1079 1082 1079 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR</italic>
###xml 1084 1090 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDZK1 </italic>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSD </italic>
###xml 1226 1227 1226 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1392 1397 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1 </italic>
###xml 1551 1555 1551 1555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR </italic>
###xml 1559 1565 1559 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDZK1 </italic>
###xml 1599 1604 1599 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1 </italic>
###xml 1608 1613 1608 1613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSD </italic>
###xml 1650 1651 1650 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1654 1659 1654 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF3 </italic>
###xml 1663 1667 1663 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGP </italic>
###xml 1790 1798 1790 1794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#945; </italic>
###xml 1912 1913 1908 1909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1944 1946 1940 1942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 2034 2041 2026 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#946; </italic>
###xml 2103 2111 2092 2096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#945; </italic>
###xml 2201 2206 2186 2191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 2293 2298 2278 2283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3</italic>
###xml 2300 2305 2285 2290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 2309 2315 2294 2300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 2463 2469 2448 2454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5</italic>
###xml 2471 2477 2456 2462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R1 </italic>
###xml 2481 2486 2466 2471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSTA </italic>
###xml 2555 2556 2540 2541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 2567 2568 2552 2553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 2741 2748 2726 2733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5 </italic>
###xml 2853 2860 2838 2845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5 </italic>
###xml 2889 2894 2874 2879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSTA </italic>
###xml 2948 2954 2933 2939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R1 </italic>
###xml 2958 2963 2943 2948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD </italic>
###xml 3051 3057 3036 3042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSAT1 </italic>
To establish that the measured differences in gene expression on the microarrays did indeed reflect the concentration of the respective mRNAs, we performed quantitative RT-PCR (Q-PCR) on a selection of 22 genes on the same RNA samples and on additional RNA preparations from different culture conditions. Standard quantities of intact total RNA or mRNA were reverse transcribed and subjected to Q-PCR. To normalise the cDNA samples we used HPRT1 (not present on the microarray) as a reference. Results have been presented relative to non-stimulated ZR-75-1 cells to facilitate direct comparison with microarray data (Table 3). In general, we found good agreement between the levels of HPRT1 and another housekeeping gene (HMBS) in our experimental samples. The expression of MYC was fairly constant in our series, with the exception of a slight decrease in EGF-stimulated ZR/EGFR cells (Table 3). This is in agreement with the results of our microarray hybridisations, which showed MYC expression to be significantly reduced only by EGF (Fig. 1). Oestrogen targets such as TFF1, PGR, PDZK1 and CTSD are indeed increased by treatment of our ZR-75-1 cells and BCAR1-transfected and BCAR3-transfected cells with oestrogen (Table 3). These genes are already elevated after 6 hours of treatment with oestrogen (not by the pure oestrogen antagonist ICI 164,384), but their levels increase further (TFF1 up to 30-fold) after prolonged oestrogen treatment, in agreement with our microarray data. After stimulation of ZR/EGFR cells with EGF, the expression of PGR and PDZK1 was completely abolished, whereas TFF1 and CTSD levels were induced under EGF (Table 3). TFF3 and MGP levels were clearly induced after long-term treatment with oestrogen and reduced after stimulation with EGF. The levels of ERalpha (not present on the array) show some decrease after treatment of ZR-75-1-derived cell lines with oestrogen (Table 3). A much stronger decrease in ERalpha levels (10-fold) is achieved after 7 days of treatment of ZR/EGFR cells with EGF. ERbeta levels were found to be reduced about 1000-fold compared with ERalpha in our cells and not strongly affected by the culture conditions. The levels of HER2/Neu (ERBB2) were decreased after treatment with both oestrogen and EGF. The expression levels of BCAR3, EGFR and BCAR1 were not strongly affected in the various cultures, except for the cells containing the introduced transgene. The observed expression modulation of IGFBP5, IL1R1 and CSTA in our microarray experiments is very well reproduced by Q-PCR (Fig. 1 and Table 3). Although oestrogen treatment causes a moderate decrease in these genes in ZR-75-1 cells, treatment of ZR/EGFR cells with EGF causes a marked effect (100-fold decrease in IGFBP5 after 7 days). The Q-PCR data also support the microarray data that BCAR3 cells have decreased levels of IGFBP5 mRNA and increased levels of CSTA mRNA in comparison with the BCAR1 and parental cells. IL1R1 and APOD levels are slightly modulated in BCAR1 cells, in agreement with the hybridisation data. PSAT1 levels were found to be further decreased in BCAR1 cells than suggested by the array experiments.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR1 </italic>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR3 </italic>
###xml 619 628 619 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 814 821 810 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#946; </italic>
###xml 852 860 845 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#945; </italic>
###xml 965 966 954 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 982 990 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER&#945; </italic>
###xml 1183 1185 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1333 1334 1314 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1345 1346 1326 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1671 1673 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1705 1707 1686 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1708 1710 1689 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1727 1728 1708 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1883 1884 1864 1865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1884 1886 1865 1867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1917 1919 1898 1900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2053 2054 2034 2035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2054 2056 2035 2037 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 2096 2100 2077 2081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1</italic>
###xml 2102 2106 2083 2087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSD</italic>
###xml 2108 2113 2089 2094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 2115 2118 2096 2099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR</italic>
###xml 2120 2126 2101 2107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDZK1 </italic>
###xml 2130 2133 2111 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYB</italic>
###xml 2156 2163 2137 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP4 </italic>
###xml 2245 2247 2226 2228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2351 2353 2332 2334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2452 2453 2433 2434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 2467 2470 2448 2451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 2472 2477 2453 2458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XBP1 </italic>
###xml 2481 2484 2462 2465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGP</italic>
###xml 2487 2492 2468 2473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STC1 </italic>
###xml 2625 2627 2606 2608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 2628 2630 2609 2611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2664 2669 2645 2650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STC2 </italic>
###xml 2730 2732 2711 2713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 2733 2735 2714 2716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2807 2812 2788 2793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STC2 </italic>
###xml 2898 2903 2879 2884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STC1 </italic>
###xml 2909 2910 2890 2891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 540 545 <span type="species:ncbi:9606">human</span>
The expression of a large proportion of genes investigated on this cDNA microarray does not alter significantly after stimulation of ZR-75-1 cells with oestrogen, or ZR/EGFR cells with EGF, or transfection of BCAR1 or BCAR3 genes. Furthermore, different ZR-75-1-derived cell clones showed very similar expression profiles after growth manipulation with oestrogen, indicating the stability of the parental cell line and the absence of extensive variation between cell clones. This result is in agreement with previous observations that this human breast cancer cell line is extremely stable and is a suitable target for in vitro insertion mutagenesis with retrovirus [16]. The growth of this cell line is completely dependent on oestrogen, and the proliferation signal is mediated primarily through ERalpha because ERbeta mRNA levels were very low. The ERalpha mRNA is readily detected in our cells by Q-PCR and is moderately decreased by oestrogen treatment (Table 3). In contrast, ERalpha mRNA is strongly decreased (about 10-fold) in EGF-treated ZR/EGFR cells, which might relate to the observation of growth interference between signalling by oestrogen and by EGF in these cells [31]. Of the 1006 significantly affected genes in our series of experiments, only few are immediate/early targets of oestrogen-activated ERalpha (Fig. 1 and Table 3). Most changes in gene expression observed in our cell model are the result of long-term culture with either oestrogen or EGF. Many genes here identified as oestrogen targets have previously been reported to be directly regulated by oestrogen using conventional northern blotting, serial analysis of gene expression (SAGE) [35] or gene expression profiling [36-40] (see also Fig. 1, 'cell lines' column). Good concordance with literature data was observed for the immediate and late targets of oestrogen in our cells (categorised data, rs = 0.42 and 0.41, respectively; P < 0.01). As expected, no association between EGF-regulated gene expression and reported oestrogen targets was seen (categorised data, rs = - 0.07). Undisputed early targets are TFF1, CTSD, CCND1, PGR, PDZK1 and MYB, whereas induction of IGFBP4 by oestrogen was reported to be dependent on the presence of serum in MCF7 cells [37]. Mostly overlapping results for oestrogen-regulated genes in MCF7 cells have been presented recently [40]. Differences between the various cell line models might explain individual differences (see Fig. 1, for example MYC, XBP1 and MGP). STC1 is rapidly induced in our experiments but has been reported not to be regulated in MCF-7 cells with the use of SAGE and microarrays [35,40]. In contrast, its family member STC2 was strongly increased by oestrogen treatment of MCF7 cells [35,37]. On our microarrays we did observe a moderate induction (1.7-fold) in STC2 transcript levels after induction with oestrogen for 6 hours, essentially parallel to STC1 (Fig. 1).
###end p 37
###begin p 38
###xml 162 171 162 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 639 640 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 640 642 640 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 650 652 650 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 811 816 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFRA1</italic>
###xml 825 829 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GJA1</italic>
###xml 831 837 831 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP4</italic>
###xml 839 844 839 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6ST</italic>
###xml 846 851 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEIS3</italic>
###xml 853 856 853 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYB</italic>
###xml 858 863 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDZK1</italic>
###xml 865 868 865 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR</italic>
###xml 870 879 870 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINA5 </italic>
###xml 883 888 883 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1 </italic>
###xml 894 895 894 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1024 1025 1024 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1025 1027 1025 1027 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1037 1039 1037 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1339 1340 1339 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1465 1466 1465 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1466 1468 1466 1468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1478 1480 1478 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1581 1582 1581 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1583 1584 1583 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 2073 2075 2073 2075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2166 2169 2166 2169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TK1</italic>
###xml 2171 2176 2171 2176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FBP1 </italic>
###xml 2180 2186 2180 2186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5</italic>
###xml 2196 2201 2196 2201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 2227 2231 2227 2231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CPE </italic>
###xml 2235 2241 2235 2241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2RY10</italic>
###xml 2296 2297 2296 2297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 2331 2336 2331 2336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R1</italic>
###xml 2338 2344 2338 2344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXM1 </italic>
###xml 2348 2352 2348 2352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PC4 </italic>
###xml 2444 2446 2444 2446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Linking expression databases derived from cell line models and clinical samples provides the opportunity to extract additional information. We have connected our in vitro gene expression data with the public results of gene expression profiling of clinical breast cancer specimens [28,41] through the Unigene cluster number. About one-fifth of the 1006 genes in our selection were reported to be associated with ER status, BRCA mutation status and/or breast cancer prognosis (Fig. 1). Comparison of the categorised data of early oestrogen-regulated gene expression and expression association with ER status reveals a positive correlation (rs = 0.21, P < 0.002). Clear examples of genes showing a positive correlation with ER status in breast carcinoma and oestrogen-induced gene expression in ZR-75-1 cells are CCND1, GFRA1, GJA1, IGFBP4, IL6ST, MEIS3, MYB, PDZK1, PGR, SERPINA5 and TFF1 (Fig. 1). Examination of the genes regulated in our cells by long-term treatment with oestrogen reveals an unexpected inverse relation (rs = - 0.23; P < 0.002) with expression association to ER status of the tumour. About half of the genes regulated by long-term oestrogen and not regulated by EGF exhibit concordance with ER status, whereas most of the genes regulated similarly by both treatments show a discordant relation with ER expression (Fig. 1). A much stronger negative relation exists between EGF-regulated gene expression and expression association with ER status (rs = - 0.43; P < 0.0001), which concurs with the established inverse relation between ER and EGFR in breast cancer [7,8]. The results of this comparison of cell line expression data with profiles of clinical samples indicate that part of the molecular markers for ER status in primary breast tumours might indeed represent genuine ER targets. Various other markers are not linked to oestrogen action but might reflect activation of the EGFR pathway in ER-negative tumour cells. Partial overlap was also reported for genes associated with breast cancer ER status and oestrogen-responsive genes in MCF7 cells [40]. Some genes reported to be associated with the prognosis of node-negative breast cancer (TK1, FBP1 and IGFBP5) or with BRCA mutation-induced disease (CPE and P2RY10) seem to be regulated by BCAR1 and/or BCAR3 (see Fig. 1). In addition, the expression of IL1R1, FOXM1 and PC4 changes markedly during the progression of normal prostate to metastasised prostate cancer [27]. These observed relations of genes regulated by BCAR1 and/or BCAR3 with clinical features of malignancies remain interesting and are targets for further study.
###end p 38
###begin p 39
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSTA</italic>
###xml 296 304 296 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPC242 </italic>
###xml 308 315 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS1 </italic>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP5</italic>
###xml 345 352 345 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NEDD4L </italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH7</italic>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BIRC5</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELL2</italic>
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXM1</italic>
###xml 576 579 576 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID1</italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R1</italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYB </italic>
###xml 596 600 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TK1 </italic>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOD</italic>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6ST </italic>
###xml 638 645 638 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS8 </italic>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1281 1282 1281 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1287 1304 1287 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 1715 1720 1715 1720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 1987 1989 1983 1985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1990 1992 1986 1988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2096 2097 2092 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 2102 2119 2098 2115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 2159 2161 2155 2157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2162 2164 2158 2160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2493 2495 2481 2483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2496 2498 2484 2486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The overall results show that BCAR1-transfected or BCAR3-transfected cells in unsupplemented cultures exhibit only modest changes in gene expression compared with unstimulated ZR-75-1 cells (Fig. 1 and Table 3). The prominent changes in gene expression induced by BCAR3 are upregulation of CSTA, HSPC242 and LGALS1 and downregulation of IGFBP5, NEDD4L and PCDH7. These genes are involved in protein degradation, cell-cell adhesion, the assembly of extracellular matrix and control of cell growth and metabolism. In BCAR1-transfected cells, upregulation of BIRC5, ELL2, FOXM1, ID1, IL1R1, MYB and TK1 and downregulation of APOD, IL6ST and LGALS8 was observed. Several of these genes modulated by BCAR1 have been shown to be important in cell signalling and in the regulation of cell proliferation or possibly in increasing cell survival. These clearly different patterns of gene expression in BCAR1 and BCAR3 transfectants indicate that signalling proceeds along alternative pathways. This contrasts with the co-occurrence of BCAR1 and BCAR3 in a protein complex in some of our cell models (Ton van Agthoven, Arend Brinkman, Lambert CJ Dorssers, unpublished results) and the functional association of BCAR1/p130Cas and BCAR3/AND-34 in cell migration [42]. From the profiles in Fig. 1 and Additional file 1 it is clear that partial overlap exists in the expression profiles of the BCAR1 and BCAR3 transfectants with both oestrogen-induced and EGF-induced cells. Most of these genes are modulated in most experiments and thus might represent expression features of proliferating ZR-75-1 cells. The remaining overlap with either oestrogen-modulated or EGF-modulated genes is limited, making it highly unlikely that the BCAR genes use major parts of these signalling pathways. This observation agrees with previous results showing that BCAR1 and BCAR3 cell lines generated by retroviral insertion mutagenesis had all lost ERalpha protein expression and did not acquire responsiveness to EGF [16,17]. Furthermore, growth of BCAR1 and BCAR3 transfectants (which are fully responsive to oestrogen; Table 3 and Additional file 1) was not stimulated by anti-oestrogen [17,18], suggesting that there is no role for ERalpha in the anti-oestrogen-resistant proliferation of these cell models. In clinical specimens, BCAR1 was found to be an independent marker (multivariate analyses also including ERalpha) for early recurrence of breast cancer and for failure of tamoxifen treatment of recurrent disease [21-24]. Because not all genes are present on this microarray and only a limited set of experimental conditions have currently been analysed in our cell model, we cannot exclude from these microarray experiments the possibility that the BCAR transfectants selectively use components of the hormonal receptor and/or growth factor receptor signalling pathways for proliferation control. In addition, growth control mediated by BCAR1 and BCAR3 might not be reflected in gene expression but could also be supervised at the level of regulatory protein activation.
###end p 39
###begin p 40
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCAR </italic>
###xml 893 901 893 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
Our results present an overview of gene expression changes after perturbation of ZR-75-1 breast cancer cells with treatment with oestrogen or EGF or by the overexpression of BCAR genes. The data suggest that oestrogen-independent cell proliferation induced by overexpression of BCAR1 or BCAR3 does not depend merely on the oestrogen-signalling or EGFR-signalling pathways. Because BCAR1 protein levels have been associated with clinical outcome for breast cancer patients, further studies are needed to resolve the underlying mechanism. This study also shows that important cell biological properties such as oestrogen-independent proliferation can be regulated in several subtle ways and thus might be hidden in the excess of gene expression differences observed in profiles of specimens from patients. The combination of expression profiles of relevant cell models, which can be manipulated in vitro, and high-quality specimens from patients might permit the identification and understanding of the important cellular pathways contributing to major clinical features of malignant diseases [43]. This information could ultimately lead to the development of improved or novel treatment strategies for breast cancer.
###end p 40
###begin title 41
Abbreviations
###end title 41
###begin p 42
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 324 326 324 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 304 310 <span type="species:ncbi:9913">bovine</span>
###xml 311 315 <span type="species:ncbi:9913">calf</span>
BCAR = Breast Cancer Anti-oestrogen Resistance; DE = differential expression; E2 = oestradiol; EGF = epidermal growth factor; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; P130Cas = Crk-associated substrate; Q-PCR = quantitative RT-PCR; R/BCS = RPMI 1640 medium supplemented with 10% bovine calf serum; rs = Spearman rank correlation; RT-PCR = reverse transcriptase-mediated polymerase chain reaction; SAGE = serial analysis of gene expression; ZR/EGFR = EGFR-transfectant cell line ZR/HERc(1A).
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The author(s) declare that they have no competing interests.
###end p 44
###begin title 45
Supplementary Material
###end title 45
###begin title 46
Additional File 1
###end title 46
###begin p 47
###xml 247 249 247 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
A TIFF file showing hierarchical clustering of gene ratios. Signal intensity tables were imported into Rosetta Resolver, combined for dye swapping and evaluated using the Incyte/UniGEM error model. A total of 2373 genes displaying at least once a P value of 0.01 or less were used for hierarchical clustering. In this colour picture, increased expression is shown in red and decreased expression is shown in green. Black represents no change and grey indicates missing data. The compared RNA samples are indicated. The gene names and log(ratios) are provided in Additional file 2.
###end p 47
###begin p 48
Click here for file
###end p 48
###begin title 49
Additional File 2
###end title 49
###begin p 50
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
An Excel file containing gene expression data, namely Incyte spot ID, accession number, sequence name and description, and the Rosetta Resolver output data columns: log(ratio), P value and log(error).
###end p 50
###begin p 51
Click here for file
###end p 51
###begin title 52
Additional File 3
###end title 52
###begin p 53
An Excel file containing all data from the actual and virtual experiments meeting the selection criteria (see Fig. 1), Unigene cluster number, gene name and description, and cited literature data with regard to oestrogen-regulated gene expression in cell lines and associations with tumour phenotypes. Ordering is in accordance with the hierarchical clustering of all genes, using the columns depicted in Fig. 1.
###end p 53
###begin p 54
Click here for file
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
The authors thank Anieta Sieuwerts (Department of Medical Oncology) for excellent support with Q-PCR experiments. Furthermore, we acknowledge Dr Guido Jenster (Department of Urology) and Dr Els Berns and Dr John Foekens (Department of Medical Oncology) for suggestions and stimulating discussions. The Biomics Core of the Erasmus MC is acknowledged for support in data management and analysis. The anti-oestrogen-resistance research is supported by grants of the Dutch Cancer Society (KWF) and the Revolving Fund of the Erasmus MC.
###end p 56
###begin article-title 57
The nuclear receptor superfamily: the second decade
###end article-title 57
###begin article-title 58
###xml 34 39 <span type="species:ncbi:9606">human</span>
Connections and regulation of the human estrogen receptor
###end article-title 58
###begin article-title 59
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Cloning of a novel receptor expressed in rat prostate and ovary
###end article-title 59
###begin article-title 60
###xml 55 60 <span type="species:ncbi:9606">human</span>
ERbeta: identification and characterization of a novel human estrogen receptor
###end article-title 60
###begin article-title 61
Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators
###end article-title 61
###begin article-title 62
Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?
###end article-title 62
###begin article-title 63
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients
###end article-title 63
###begin article-title 64
###xml 122 127 <span type="species:ncbi:9606">human</span>
Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry
###end article-title 64
###begin article-title 65
Aromatase and its inhibitors: significance for breast cancer therapy
###end article-title 65
###begin article-title 66
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators
###end article-title 66
###begin article-title 67
Cellular and molecular pharmacology of antiestrogen action and resistance
###end article-title 67
###begin article-title 68
###xml 95 100 <span type="species:ncbi:9606">human</span>
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
###end article-title 68
###begin article-title 69
Oestrogen receptor: a stable phenotype in breast cancer
###end article-title 69
###begin article-title 70
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer
###end article-title 70
###begin article-title 71
Tamoxifen resistance in breast cancer: elucidating mechanisms
###end article-title 71
###begin article-title 72
###xml 40 45 <span type="species:ncbi:9606">human</span>
Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site
###end article-title 72
###begin article-title 73
###xml 92 97 <span type="species:ncbi:9606">human</span>
Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells
###end article-title 73
###begin article-title 74
###xml 9 14 <span type="species:ncbi:9606">human</span>
BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells
###end article-title 74
###begin article-title 75
Integrin signalling: a new cas(t) of characters enters the stage
###end article-title 75
###begin article-title 76
Functions of the adapter protein Cas: signal convergence and the determination of cellular responses
###end article-title 76
###begin article-title 77
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment
###end article-title 77
###begin article-title 78
###xml 60 65 <span type="species:ncbi:9606">human</span>
Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue
###end article-title 78
###begin article-title 79
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer
###end article-title 79
###begin article-title 80
###xml 33 41 <span type="species:ncbi:9606">patients</span>
The prognostic value of BCAR1 in patients with primary breast cancer
###end article-title 80
###begin article-title 81
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
###end article-title 81
###begin article-title 82
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
###end article-title 82
###begin article-title 83
Delineation of prognostic biomarkers in prostate cancer
###end article-title 83
###begin article-title 84
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 84
###begin article-title 85
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
###end article-title 85
###begin article-title 86
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 86
###begin article-title 87
###xml 96 101 <span type="species:ncbi:9606">human</span>
Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
###end article-title 87
###begin article-title 88
An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression
###end article-title 88
###begin article-title 89
Fundamentals of experimental design for cDNA microarrays
###end article-title 89
###begin article-title 90
###xml 46 51 <span type="species:ncbi:9606">human</span>
Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations
###end article-title 90
###begin article-title 91
Effects of estrogen on global gene expression: identification of novel targets of estrogen action
###end article-title 91
###begin article-title 92
###xml 59 64 <span type="species:ncbi:9606">human</span>
Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling
###end article-title 92
###begin article-title 93
Regulation of DNA replication fork genes by 17beta-estradiol
###end article-title 93
###begin article-title 94
Development of cDNA microarray for expression profiling of estrogen-responsive genes
###end article-title 94
###begin article-title 95
###xml 67 72 <span type="species:ncbi:9606">human</span>
The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application
###end article-title 95
###begin article-title 96
The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles
###end article-title 96
###begin article-title 97
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns
###end article-title 97
###begin article-title 98
Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3
###end article-title 98
###begin article-title 99
###xml 78 83 <span type="species:ncbi:9606">human</span>
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer
###end article-title 99
###begin article-title 100
Cluster analysis and display of genome-wide expression patterns
###end article-title 100
###begin title 101
Figures and Tables
###end title 101
###begin p 102
###xml 155 157 155 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 512 514 512 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 731 733 731 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1357 1362 1357 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
Expression changes of selected genes in ZR-75-1-derived cell lines, and their relation to reported clinical phenotypes. Average gene expression ratios (log10) in ZR-75-1 cells stimulated with oestrogen for 6 hours (E6hr) or continuously (Econt), of ZR/EGFR cells stimulated with epidermal growth factor for 7 days (EGF), of BCAR1-transfected or BCAR3-transfected ZR-75-1 cells versus unstimulated ZR-75-1 cells are indicated. A selection of 234 sequences was made from the 1006 sequences showing at least once a P value of 0.01 or less and exhibiting at least once a |DE| of more than 1.60. Individual data points of combined swapped and of virtual experiments were only included when either one of the following criteria was met: P < 0.051 or log(error) < 0.1761 or |log(ratio)| > 1.5 x log(error). This procedure eliminates most of the unreliable data points. Genes were hierarchically clustered by using Spotfire. A colour picture was made with TreeView [44]. Increased expression is shown in red and decreased expression is shown in green. Black represents no change and white indicates missing data. In addition, the reported inducing (red) or reducing (green) effects of oestrogen stimulation in cell line models [35-37,39,40] and the correlation (red, positive; green, negative) of individual genes with breast cancer oestrogen receptor (ER) status, BRCA mutation status (BRCA) and prognosis of disease recurrence is indicated [28,41]. Genes investigated with quantitative reverse transcriptase-mediated polymerase chain reaction have been marked with an asterisk. The complete list of 1006 genes with attached information is presented in Additional file 3.
###end p 102
###begin p 103
Hybridisation experiments
###end p 103
###begin p 104
###xml 106 112 <span type="species:ncbi:9913">bovine</span>
###xml 113 117 <span type="species:ncbi:9913">calf</span>
RNA samples were prepared from cell lines pretreated for 5 days in RPMI 1640 medium supplemented with 10% bovine calf serum (R/BCS) and subsequently cultured for the indicated durations in R/BCS medium supplemented with oestrogen (E2), epidermal growth factor (EGF) or R/BCS medium without further additions. All hybridisations were performed in duplicate with swapping of the dyes.
###end p 104
###begin p 105
Primer information
###end p 105
###begin p 106
F, forward; R, reverse. The gene names are defined in Additional file 3.
###end p 106
###begin p 107
Relative gene expression in ZR-75-1-derived cell lines
###end p 107
###begin p 108
All expression levels have been normalised for HPRT1 levels and are presented relative to non-stimulated ZR-75-1 cells. The gene names are defined n Additional file 3.
###end p 108
###begin p 109
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aThe nature and duration of the culture additions (ICI, oestrogen antagonist ICI 164,384).
###end p 109
###begin p 110
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bThe number of biological replicates and total number of analyses (in parentheses).
###end p 110
###begin p 111
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
cGene expression level was set at 1.0 for non-stimulated ZR-75-1 cells and the detection threshold cycle (Ct) value for each gene is shown in parentheses (23 for HPRT1).
###end p 111
###begin p 112
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dQuantitative polymerase chain reaction with assay on demand; others with SYBR green.
###end p 112

